Published in J Clin Microbiol on May 23, 2007
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother (2012) 1.29
In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J Clin Microbiol (2008) 1.10
First comprehensive evaluation of the M.I.C. evaluator device compared to Etest and CLSI reference dilution methods for antimicrobial susceptibility testing of clinical strains of anaerobes and other fastidious bacterial species. J Clin Microbiol (2012) 1.09
Clinical and microbiological characteristics of tigecycline non-susceptible Klebsiella pneumoniae bacteremia in Taiwan. BMC Infect Dis (2014) 0.97
In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital. Eur J Clin Microbiol Infect Dis (2008) 0.90
Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology. Eur J Clin Microbiol Infect Dis (2008) 0.89
Influence of media and testing methodology on susceptibility to tigecycline of Enterobacteriaceae with reported high tigecycline MIC. J Clin Microbiol (2010) 0.85
Comparative evaluation of tigecycline susceptibility testing methods for expanded-spectrum cephalosporin- and carbapenem-resistant gram-negative pathogens. J Clin Microbiol (2012) 0.80
Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi. J Clin Microbiol (2014) 0.75
Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria. J Clin Microbiol (1991) 4.79
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother (1999) 4.44
Evaluation of the E test, a novel method of quantifying antimicrobial activity. J Antimicrob Chemother (1991) 4.06
Evaluation of the E test for susceptibility testing of anaerobic bacteria. J Clin Microbiol (1991) 2.59
The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis (2005) 2.57
The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis (2005) 2.33
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother (2005) 1.84
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis (2005) 1.73
Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother (2005) 1.56
Tetracycline therapy: update. Clin Infect Dis (2003) 1.54
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis (2005) 1.33
Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother (2004) 1.22
Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today (Barc) (2005) 1.02
Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother (2006) 1.00
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother (2003) 3.00
In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob Agents Chemother (2002) 2.48
Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother (2005) 2.22
Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents (2008) 2.03
AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother (2003) 1.98
Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis (2008) 1.97
Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother (2003) 1.97
A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother (2005) 1.88
Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol (2008) 1.86
Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother (2005) 1.84
AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother (2007) 1.79
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis (2005) 1.73
In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother (2006) 1.68
RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist (2007) 1.66
MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother (2007) 1.65
Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother (2006) 1.60
Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis (2002) 1.60
Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother (2005) 1.56
The efficacy of P6 acupressure with sea-band in reducing postoperative nausea and vomiting in patients undergoing craniotomy: a randomized, double-blinded, placebo-controlled study. J Neurosurg Anesthesiol (2015) 1.40
Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochim Biophys Acta (2003) 1.35
Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis (2010) 1.35
A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital. J Antimicrob Chemother (2005) 1.33
Further evidence that a cell wall precursor [C(55)-MurNAc-(peptide)-GlcNAc] serves as an acceptor in a sorting reaction. J Bacteriol (2002) 1.29
Late stage antibacterial drugs in the clinical pipeline. Curr Opin Microbiol (2007) 1.28
Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J Am Chem Soc (2002) 1.28
In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother (2003) 1.28
AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother (2005) 1.27
In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis (2005) 1.24
Rapid clinical bacteriology and its future impact. Ann Lab Med (2012) 1.16
5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases. Bioorg Med Chem (2007) 1.16
Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results. J Clin Microbiol (2008) 1.14
Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother (2008) 1.13
Comparative in vitro activities of AC98-6446, a novel semisynthetic glycopeptide derivative of the natural product mannopeptimycin alpha, and other antimicrobial agents against gram-positive clinical isolates. Antimicrob Agents Chemother (2004) 1.13
Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene. Emerg Infect Dis (2016) 1.12
In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors. Antimicrob Agents Chemother (2004) 1.12
Evaluation of Etest MBL for detection of blaIMP-1 and blaVIM-2 allele-positive clinical isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol (2005) 1.09
Characterization and sequence analysis of extended-spectrum-{beta}-lactamase-encoding genes from Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother (2008) 1.08
Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic. Drugs Today (Barc) (2005) 1.02
Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother (2006) 1.00
Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria. J Med Chem (2004) 0.99
Phenyl thiazolyl urea and carbamate derivatives as new inhibitors of bacterial cell-wall biosynthesis. Bioorg Med Chem Lett (2004) 0.98
Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob Agents Chemother (2007) 0.97
Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria. Antimicrob Agents Chemother (2004) 0.96
Muraymycins, novel peptidoglycan biosynthesis inhibitors: synthesis and SAR of their analogues. Bioorg Med Chem Lett (2003) 0.96
Novel ether derivatives of mannopeptimycin glycopeptide antibiotic. Bioorg Med Chem Lett (2003) 0.95
Pyrosequencing using the single-nucleotide polymorphism protocol for rapid determination of TEM- and SHV-type extended-spectrum beta-lactamases in clinical isolates and identification of the novel beta-lactamase genes blaSHV-48, blaSHV-105, and blaTEM-155. Antimicrob Agents Chemother (2008) 0.94
Global incidence of carbapenemase-producing Escherichia coli ST131. Emerg Infect Dis (2014) 0.94
Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model. Oncogene (2005) 0.93
MYC can enforce cell cycle transit from G1 to S and G2 to S, but not mitotic cellular division, independent of p27-mediated inihibition of cyclin E/CDK2. Cell Cycle (2006) 0.93
Use of structure-based drug design approaches to obtain novel anthranilic acid acyl carrier protein synthase inhibitors. J Med Chem (2005) 0.92
Mannopeptimycin esters and carbonates, potent antibiotic agents against drug-resistant bacteria. Bioorg Med Chem Lett (2004) 0.91
Novel alpha-pyrones produced by a marine Pseudomonas sp. F92S91: taxonomy and biological activities. J Antibiot (Tokyo) (2003) 0.90
Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors. Bioorg Med Chem (2004) 0.89
Identification and sequence of a tet(M) tetracycline resistance determinant homologue in clinical isolates of Escherichia coli. J Bacteriol (2006) 0.89
RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex. Microb Drug Resist (2010) 0.88
Resistance development profiling of piperacillin in combination with the novel {beta}-lactamase inhibitor BLI-489. J Antimicrob Chemother (2009) 0.86
Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. Antimicrob Agents Chemother (2008) 0.85
Pyrazolidine-3,5-diones and 5-hydroxy-1H-pyrazol-3(2H)-ones, inhibitors of UDP-N-acetylenolpyruvyl glucosamine reductase. J Med Chem (2006) 0.84
Anthranilate 4H-oxazol-5-ones: novel small molecule antibacterial acyl carrier protein synthase (AcpS) inhibitors. Bioorg Med Chem Lett (2004) 0.83
Analysis of chromosome 10 aberrations in rat endometrial cancer-evidence for a tumor suppressor locus distal to Tp53. Int J Cancer (2007) 0.83
Design and synthesis of indolo[2,3-a]quinolizin-7-one inhibitors of the ZipA-FtsZ interaction. Bioorg Med Chem Lett (2004) 0.83
Pulvinones as bacterial cell wall biosynthesis inhibitors. Bioorg Med Chem Lett (2005) 0.83
The effect of ACTH stimulation on cortisol and progesterone concentrations in intact and ovariohysterectomized domestic cats. Theriogenology (2006) 0.82
Combinatorial synthesis of substituted 3-(2-indolyl)piperidines and 2-phenyl indoles as inhibitors of ZipA-FtsZ interaction. Bioorg Med Chem (2004) 0.82
Structure-based design of carboxybiphenylindole inhibitors of the ZipA-FtsZ interaction. Org Biomol Chem (2003) 0.81
3,5-dioxopyrazolidines, novel inhibitors of UDP-N- acetylenolpyruvylglucosamine reductase (MurB) with activity against gram-positive bacteria. Antimicrob Agents Chemother (2006) 0.81
Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection. Antimicrob Agents Chemother (2009) 0.80
Synthesis and antibacterial activity of 9-substituted minocycline derivatives. Bioorg Med Chem Lett (2005) 0.80
Identification of compounds that inhibit late steps of peptidoglycan synthesis in bacteria. J Antibiot (Tokyo) (2002) 0.80
In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. Diagn Microbiol Infect Dis (2010) 0.80
Naphthyl tetronic acids as multi-target inhibitors of bacterial peptidoglycan biosynthesis. ChemMedChem (2007) 0.79
Assessment of allele dosage at polymorphic microsatellite loci displaying allelic imbalance in tumors by means of quantitative competitive-polymerase chain reaction. Cancer Genet Cytogenet (2005) 0.79
2-Phenyl-5,6-dihydro-2H-thieno[3,2-c]pyrazol-3-ol derivatives as new inhibitors of bacterial cell wall biosynthesis. Bioorg Med Chem Lett (2003) 0.79
Synthesis and evaluation of ether and halogenated derivatives of mannopeptimycin glycopeptide antibiotics. Bioorg Med Chem Lett (2003) 0.78
Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. Antimicrob Agents Chemother (2005) 0.78
In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis (2007) 0.77
Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics. Bioorg Med Chem Lett (2003) 0.76
Tigecycline: a case study. Expert Opin Drug Discov (2007) 0.75
Recurrent episodes of shock-like syndrome caused by the same strain of vancomycin-resistant Enterococcus faecium in a pediatric patient. Microb Drug Resist (2003) 0.75
A novel antibiotic bone assay by liquid chromatography/tandem mass spectrometry for quantitation of tigecycline in rat bone. J Pharm Biomed Anal (2007) 0.75